A pharmacovigilance study to evaluate safety of AVODART (dutasteride) administration 0,5 mg once daily, for 52 weeks, in subjects with benign prostate hyperplasia

Trial Profile

A pharmacovigilance study to evaluate safety of AVODART (dutasteride) administration 0,5 mg once daily, for 52 weeks, in subjects with benign prostate hyperplasia

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2008

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top